Repositioning Candidate Details
| Candidate ID: | R0146 |
| Source ID: | DB00513 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Aminocaproic acid |
| Synonyms: | |
| Molecular Formula: | C6H13NO2 |
| SMILES: | NCCCCCC(O)=O |
| Structure: |
|
| DrugBank Description: | An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. |
| CAS Number: | 60-32-2 |
| Molecular Weight: | 131.1729 |
| DrugBank Indication: | For use in the treatment of excessive postoperative bleeding. |
| DrugBank Pharmacology: | Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein (a), a risk factor for vascular disease. |
| DrugBank MoA: | Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a). |
| Targets: | Plasminogen; Tissue-type plasminogen activator; Apolipoprotein(a) |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |